Elevated Expression of CD109 in Esophageal Squamous Cell Carcinoma
- 205 Downloads
To the Editor,
Esophageal squamous cell carcinoma (ESCC) accounts for approximately one-sixth of all cancer-related mortality, occurring at a higher incidence in Asian countries . Though the effectiveness of surgical treatments has significantly improved, the prognosis of ESCC remains poor, with a 5-year survival rate of less than 10 % . Recent studies suggest that the transforming growth factor-β (TGF-β) signaling may involve in malignancy development of ESCC [2, 3]. Altered expression of TGF-β receptors contributes to ESCC progression, and elevated expression of inhibitory proteins of TGF-β signaling correlates with poor prognosis of ESCC . CD109, a member of the α2-macroglobulin/complement family, is a co-receptor of TGF-β1 . CD109 suppresses TGF-β signaling by promoting internalization of TGF-β receptors . The transcription of CD109 is up-regulated in some ESCC samples . However, the protein level of CD109 in ESCCs has not yet been examined. In this limited...
KeywordsEsophageal Squamous Cell Carcinoma CD109 Expression CD109 Esophageal Squamous Cell Carcinoma Patient Squamous Epithelial Cell
This study was supported by Shandong Taishan Scholarship (Ju Liu) from Shandong Provincial Government. Ju Liu confirms that the work was performed independence from the sponsors and the content of the article has not been influenced by the sponsors.
Guarantor of the article: Ju Liu, Zhongmin Jiang
Specific author contributions:
FD, FL, YS, XL: Data collection, analysis and interpretation; drafting the manuscript; final approval of the version to be published.
ZJ, JL: project conception/initiation; experimental design; drafting of the manuscript; critical revision; final approval of the version to be published.
Conflict of interest
- 3.Megumi K, Ishigami S, Uchikado Y, Kita Y, Okumura H, Matsumoto M, Uenosono Y, Arigami T, Kijima Y, Kitazono M, Shinchi H, Ueno S, Natsugoe S (2012) Clinicopathological significance of BMP7 expression in esophageal squamous cell carcinoma. Ann Surg Oncol 19(6):2066–2071. doi: 10.1245/s10434-011-2024-5 PubMedCentralCrossRefPubMedGoogle Scholar
- 9.Cuppini L, Calleri A, Bruzzone MG, Prodi E, Anghileri E, Pellegatta S, Mancuso P, Porrati P, Di Stefano AL, Ceroni M, Bertolini F, Finocchiaro G, Eoli M (2013) Prognostic value of CD109+ circulating endothelial cells in recurrent glioblastomas treated with bevacizumab and irinotecan. PLoS One 8(9):e74345. doi: 10.1371/journal.pone.0074345 PubMedCentralCrossRefPubMedGoogle Scholar